94 related articles for article (PubMed ID: 8328213)
1. Hirudin in the treatment of arterial and venous thrombotic diseases: a new perspective.
Büller HR
Z Kardiol; 1993; 82 Suppl 2():81-2. PubMed ID: 8328213
[TBL] [Abstract][Full Text] [Related]
2. Hirudin as alternative anticoagulant--a historical review.
Markwardt F
Semin Thromb Hemost; 2002 Oct; 28(5):405-14. PubMed ID: 12420235
[TBL] [Abstract][Full Text] [Related]
3. [Hirudin and hirudin fragments].
Deschamps A; Samama M
Ann Cardiol Angeiol (Paris); 1992 Oct; 41(8):A49-53. PubMed ID: 1298182
[TBL] [Abstract][Full Text] [Related]
4. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
Haas S
Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
[TBL] [Abstract][Full Text] [Related]
5. Approaches to the treatment of unstable angina and non-Q wave myocardial infarction.
Cohen M
Can J Cardiol; 1998 Aug; 14 Suppl E():11E-14E. PubMed ID: 9779027
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group.
Schiele F; Lindgaerde F; Eriksson H; Bassand JP; Wallmark A; Hansson PO; Grollier G; Sjo M; Moia M; Camez A; Smyth V; Walker M
Thromb Haemost; 1997 May; 77(5):834-8. PubMed ID: 9184388
[TBL] [Abstract][Full Text] [Related]
7. [New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)].
Schächinger V; Zeiher AM
Z Kardiol; 1995 Sep; 84(9):651-67. PubMed ID: 8525667
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention.
Mehta SR; Eikelboom JW; Rupprecht HJ; Lewis BS; Natarajan MK; Yi C; Pogue J; Yusuf S
Eur Heart J; 2002 Jan; 23(2):117-23. PubMed ID: 11785993
[TBL] [Abstract][Full Text] [Related]
9. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
Cirillo R; Lippi A; Subissi A; Agnelli G; Criscuoli M
Thromb Haemost; 1996 Sep; 76(3):384-92. PubMed ID: 8883275
[TBL] [Abstract][Full Text] [Related]
10. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
Rübsamen K; Hornberger W
Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin.
Monreal M; Costa J; Salva P
Drugs Aging; 1996 Mar; 8(3):171-82. PubMed ID: 8720743
[TBL] [Abstract][Full Text] [Related]
12. [Hirudin: the relative failure of a very promising molecule].
Aiach M
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1485-90. PubMed ID: 9092407
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular drug highlight: hirudin.
Cheng-Lai A
Heart Dis; 1999; 1(1):41-9. PubMed ID: 11720603
[TBL] [Abstract][Full Text] [Related]
14. Hirudin for prophylaxis and treatment of deep vein thrombosis.
Kemkes-Matthes B
Semin Thromb Hemost; 2002 Oct; 28(5):455-8. PubMed ID: 12420241
[TBL] [Abstract][Full Text] [Related]
15. [The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins].
López-Sendón J; López de Sá E; Rubio Sanz R; Delcán Domínguez JL
Rev Esp Cardiol; 1999; 52 Suppl 1():76-89. PubMed ID: 10364817
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
17. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
18. Hirudin in acute coronary syndromes.
van de Loo A; Bode C
Semin Thromb Hemost; 2002 Oct; 28(5):459-66. PubMed ID: 12420242
[TBL] [Abstract][Full Text] [Related]
19. Direct antithrombins: new perspectives in cardiovascular medicine.
Lettino M; Toschi V
Curr Med Chem Cardiovasc Hematol Agents; 2004 Jul; 2(3):267-75. PubMed ID: 15320792
[TBL] [Abstract][Full Text] [Related]
20. Emerging anticoagulants: mechanism of action and future potential.
Klement P; Rak J
Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
